Karyopharm 2025 Q3 Earnings Net Loss Narrows Slightly Despite Revenue Growth

Karyopharm (KPTI) reported Q3 2025 earnings on Nov 3, 2025, with results that missed analyst expectations. , , exceeding estimates. . , aligning with previous projections.

Revenue

Driven by XPOVIO’s performance in multiple myeloma, , . Product revenue, net, , reflecting sustained demand in the U.S. market, , bolstered by milestone payments from international partners.

Earnings/Net Income

, . However, , . Despite cost discipline, the loss underscores ongoing financial challenges, . The EPS, while slightly better, still represents a significant miss relative to Wall Street estimates.

Post-Earnings Price Action Review

Following the earnings release, . , reflecting mixed investor sentiment. The post-earnings reaction highlights the market’s cautious optimism about the company’s financial flexibility and clinical progress, despite persistent losses.

CEO Commentary

, CEO, emphasized clinical milestones, including the completed SENTRY Phase III trial in myelofibrosis, . He cited XPOVIO’s strength in multiple myeloma and disciplined cost management as key drivers of revenue growth. Strategic priorities include advancing SENTRY, expanding the XPOVIO franchise, and maintaining financial prudence ahead of top-line data in March 2026.

Guidance

, . . , . CFO underscored disciplined cost management and financing proceeds as factors supporting the revised expense ranges.

Additional News

1. Inducement Grants, .

2. SENTRY Trial Update, . CEO Paulson highlighted the potential for plus ruxolitinib to redefine treatment standards.

3. SEC 10-Q Filing.